

EUROPEAN
CURRICULUM VITAE
FORMAT



PERSONAL INFORMATION

Name	ALBINA ALLAJBEJ
Address	Fondazione IRCCS Istituto Nazionale Tumori Via G. Venezian 1, 20133 (MI)
Phone	+39 0223902480
E-mail	albina.allajbej@istitutotumori.mi.it
Nationality	Albanian
Date of birth	28/05/1986

WORKING EXPERIENCE

Date	16/06/2021- current Radiation Oncologist Radiotherapy Department Fondazione IRCCS Istituto Nazionale di tumori, Via Venezian 1, Milan Fields of expertise: Thoracic oncology, Adult's sarcomas and rare tumors, palliatian Active member in multidisciplinary meeting of clinical cases of thoracic oncology (lung cancer, lung metastasis, mesothelioma, thymoma) and adult sarcomas (soft tissue and bone sarcomas). Multidisciplinary evaluation of thoracic oncology and sarcoma patients Board member of quality and risk manual Co-investigator in clinical trials
Date	From 01/04/2020 to 15/06/2021 Radiation Oncologist Assistant Radiotherapy 1 Department Fondazione IRCCS Istituto Nazionale di tumori, Via Venezian 1, Milan Thoracic oncology ad Adult's sarcomas and rare tumors Active participation in multidisciplinary meeting of clinical cases of thoracic oncology (lung cancer, mesothelioma, thymoma) and sarcomas Multidisciplinary evaluation of thoracic oncology and sarcoma patients Board member of quality and risk assessment
Date	From 01/11/2015 to 31/10/2019 Residency Internship in Radiotherapy – University of Aquila Radiotherapy Department - SS. Annunziata Hospital, Chieti – University of Chieti-Pescara
Date	From 01/07/2019 to 30/09/2019 Visiting Physician Département de Radiothérapie -Centre Léon Bérard, Lyon, France
Date	From 01/07/2019 to 30/09/2019 Fellowship Medical Oncology Department - A.O. Ospedale civile di Legnano "G.Fornaroli", Magenta (MI)

EDUCATION AND TRAINING

- Date From 01/11/2015 to 31/10/2019
Radiation Oncology Residency at the SS. Annunziata Hospital, G. D'Annunzio University of Chieti-University of L'Aquila (Italy)
- Date 26/11/2019
Radiation oncology board certificate
Thesis: The potential benefit of Proton Therapy in Oropharyngeal Cancer: Where are the evidences? Mentors: Prof. Vincent Grégoire, Prof. Domenico Genovesi
- Date From 01/07/2019 to 30/09/2019
Observership, mentor Prof. Vincent Grégoire
Département de Radiothérapie, Centre Léon Bérard, Lyon (Francia)
- Date From 17/06/2019 to 21/06/2019
INTERACTS Course- Interventional Radiotherapy Active Teaching School, Gemelli ART, Università Cattolica Sacro Cuore, Gemelli, Roma
- Date From 03/03/2019 to 07/03/2019
ESTRO School - ESTRO course on Basic Clinical Radiobiology, Brussels (Belgium)
- Date From 01/03/2015 to 30/10/2015
Clinical research scholarship in the department of Medical Oncology at the Legnano Civil Hospital, G. Fornaroli, Magenta, Milan (Italy)
- Date 28/03/2014
M.D. (Doctor of Medicine) degree at Faculty of Medicine, University of Milan (Italy)
Thesis: Breast cancer in patients greater than 80 years old: analysis of mono-institutional experience, Mentor Prof. Paolo Foa
Internship in Medical Oncology Department at the San Paolo Hospital, Milan (Italy)
- Date June 2005
High school diploma
Mehmet Akif Turkish College, Tirana (Albania)

MOTHER TONGUE **Albanian**

OTHER LANGUAGES **Italian:** Proficient user
English: Upper intermediate user
Turkish: Intermediate user
German: Elementary/intermediate user

PERSONAL AND PROFESSIONAL SKILLS

Excellent communication and relational skills.
Ability to work under pressure. Decision making and time management
Constructive attitude and excellent sense of adaptability due to attendance of multicultural frameworks.
Matured experience in radiotherapy Linear Accelerators contouring and treatment planning software (Eclipse Aria, RayStation, Oncentra MasterPlan, Monaco, Focal), treatment delivery (Varian Clinac600, Varian DHX, Varian DBX, Varian truebeam Elekta Synergy Agility, Elekta Precise, VersaHD, Helical Tomotherapy), IGRT, SBRT e SRS.
Matured clinical experience in Onco-Hematology and Radiation Oncology Day Hospital, First-Visit and Follow-Up consultations

Excellent Computer skills; knowledge and use of Microsoft Windows e IOS

ADDITIONAL INFORMATIONS

- Member of Italian association of radiation and clinical oncology (AIRO)
- Member of Italian Sarcoma Group (ISG)
- Member of Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG)
- Member of European Society for Radiotherapy and Oncology (ESTRO)
- Member of Medical order of Milan since 23/09/2014
- ICH Good Clinical Practice E6 (R2) certification
- Mentoring for Pre-Med shadowing program, ATLANTIS
- Tutoring for residents in Medical physics, University of Milan
- Participation in several national and international courses/congresses /seminars/webinar/web meetings
- Co-author of several papers
- Co-author of several abstracts/posters in AIRO/ESTRO congresses
- 19/12/2017: **Quality & Safety 2017 Award** for the project "Use of In-Vivo Dosimetry during Radiotherapy treatment sessions aimed to improve Quality Control of Treatment Planning accuracy. » At Cure Quality and Safety Day, ASL 2 Abruzzo, Chieti.
- Basic Life Support (BLS) certification

CO-INVESTIGATOR OF CLINICAL TRIALS

- A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC).
- A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC).
- Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK-7684A Versus Concurrent Chemoradiotherapy followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III NSCLC
- BRIDGE trial: Phase II trial of durvalumaB and chemotheRapy Induction followed by Durvalumab and radiotherapy in larGe volumE stage III NSCLC
- Phase I-II prospective trial, multicenter, open label, exploring the combination of Trabectedin plus RAdiotherapy in Soft Tissue Sarcoma patients. Protocol Code: TRASTS
- A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032)

Milan, 06/02/2023

Firma



Publications:

- Silvia Molinelli, Giuseppe Magro, Andrea Mairani, **Albina Allajbej**, Alfredo Mirandola, Agnieszka Chalaszczyk, Sara Imperato, Mario Ciocca, Maria Rosaria Fiore, Ester Orlandi. How LEM-based RBE and dose-averaged LET affected clinical outcomes of sacral chordoma patients treated with carbon ion radiotherapy. *Radiother oncol* 2021 oct;163:209-214. Doi: 10.1016/j.radonc.2021.08.024. Epub 2021 sep 17.
- Marianna Trignani, Angelo Di Pilla, Consuelo Rosa, Marzia Borgia, David Fasciolo, Lucrezia Gasparini, Fiorella Di Guglielmo, **Albina Allajbej**, Marta Di Francesco, Gianluca Falcone, Francesca Vitullo, Adelchi Croce, Domenico Genovesi and Luciana Caravatta. *Multimodal evaluation of voice outcome in early glottic cancers treated with definitive radiotherapy. Cancer Diagnosis & Prognosis 1: 143-149 (2021) doi: 10.21873/cdp.10019.*
- Lucia Anna Ursini, Marianna Nuzzo, Consuelo Rosa, Fiorella Cristina Di Guglielmo, Monica Di Tommaso, Marianna Trignani, Marzia Borgia, **Albina Allajbej**, Fabiola Patani, Clelia Di Carlo, Annamaria Porreca, Marta Di Nicola, Domenico Genovesi And Luciana Caravatta. *Quality of life in early breast cancer patients: a prospective observational study using the fact-b questionnaire. In vivo may 2021, 35 (3) 1821-1828*
- **Albina Allajbej**. *AIRO'S theoretical-practical course on contouring of paranasal sinus cancers. ESTRO Newsletter May-June 2019; Young ESTRO.*
- Antonietta Augurio, Saide Di Biase, **Albina Allajbej**, Piero Maria Bianchi. *Le terapie di supporto in radioterapia: una guida pratica. Gruppo airo l.a.m. edizione 2018. Cap. 2. Tossicità nei trattamenti del distretto testa-collo. Disfagia ; ISBN-10: 8894394905*
- Rosa C, Di Tommaso M, Caravatta L, Vinciguerra A, Augurio A, Perrotti F, **Allajbej A**, Regoli M, Zecca IA, Di Nicola M, Genovesi D. *Assessment of bowel and anal sphincter function after neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Tumori. 2018;104:121-127*
- Falco MD, Giancaterino S, De Nicola A, Adorante N, De Lorenzo RG, Di Tommaso M, Vinciguerra A, Trignani M, Perrotti F, **Allajbej A**, Fidanzio A, Greco F, Grusio M, Genovesi D, Piermattei A. *A feasibility study for in vivo dosimetry procedure in routine clinical practice. TechnolCancer ResTreat. 2018;17: 1-8*
- Daniela Falco M, Giancaterino S, D'Andrea M, Gimenez De Lorenzo R, Trignani M, Caravatta L, Di Carlo C, Di Biase S, **Allajbej A**, Genovesi D. *Hippocampal sparing approach in fractionated stereotactic brain vmat radio therapy: a retrospective feasibility analysis. J Appl clinmedphys. 2018; 19:86-93.*
- Trignani M, Laus M, Mastronardi V, Leone O, De Rosa M, Campitelli G, Di Pilla A, Santarelli G, **Allajbej A**, Pamio A, Genovesi D, Croce A. *Nutritional management for patients with head and neck cancer: the second step of an italian survey. The opinion of italian otolaryngologists. Otolaryngol (Sunnyvale).2016; 6: 223.*